News

Mahamaya Lifesciences Limited submitted a certificate to the BSE Limited on October 8, 2026, detailing securities dematerialized and rematerialized for the quarter ended September 30, 2026, as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, with KFin Technologies Limited acting as the registrar and share transfer agent.

Mahamaya Lifesciences Limited announced changes to its management, effective November 1, 2026, including the re-designation of Krishnamurthy Ganesan from Managing Director to Chairman and the re-designation of Prashant Krishnamurthy as Managing Director. The company also approved the regularization and appointment of Dr. Bhagirath Choudhary as Independent Director for a three-year term starting August 25, 2026, and the re-appointment of both Dr. Gopal Krishna Raju and Dr. Charudatta Digambar Mayee as Independent Directors for second three-year terms beginning December 11, 2026.

Mahamaya Lifesciences Limited informed the BSE Limited that the trading window for dealing in the company`s securities will be closed for all insiders, designated persons, and their immediate relatives from October 01, 2026, until 48 hours after the declaration of the un-audited financial results (standalone and consolidated) for the half year ended September 30, 2026, with the date of the board meeting to consider and approve the results to be announced later.

Mahamaya Lifesciences will hold a meeting of the Board of Directors of the Company on 25 May 2026.

Mahamaya Lifesciences will hold a meeting of the Board of Directors of the Company on 2 December 2025.Powered by Capital Market - Live News